DSIP vs Orexin-A

What Are DSIP and Orexin-A?

DSIP (Delta-Sleep-Inducing Peptide) is a Neuropeptide sleep modulator. Natural neuropeptide isolated in 1974 from rabbit cerebral venous blood during induced sleep. It is researched for improved sleep quality, increased slow-wave sleep, reduced sleep latency, stress reduction, improved sleep efficiency.

Orexin-A (Hypocretin-1) is a Neuropeptide hormone. Naturally occurring peptide synthesized in the hypothalamus, regulating sleep-wake cycles and arousal. It is researched for increased wakefulness and arousal, cognitive function in narcolepsy, pain modulation.

While both are popular research peptides, they work through fundamentally different mechanisms and serve different primary purposes.

How Do DSIP and Orexin-A Work Differently?

DSIP mechanism: Promotes slow-wave (delta) sleep by stimulating acetyltransferase activity through α1 adrenergic receptors. Modulates corticotropin-releasing factor (CRF) pathways to reduce the stress response. Regulates melatonin and other sleep-promoting hormone cascades to normalize disrupted sleep architecture.

Orexin-A mechanism: Activates both OX1R and OX2R G-protein coupled receptors, increasing intracellular calcium through phospholipase C signaling. Broadly activates arousal neural networks including dopaminergic, noradrenergic, histaminergic, and cholinergic systems to promote wakefulness and prevent cataplexy.

These distinct mechanisms are why the two peptides are often used for different research goals — or combined to target multiple pathways.

How Do the Dosing Protocols Compare?

DSIP: 100-300 mcg administered once daily in the evening via subcutaneous injection or intravenous. Half-life: not established. Cycle: 4-12 weeks.

Orexin-A: not established for human peptide administration administered single dose in research protocols via intranasal (experimental human), intracerebroventricular (animal studies). Half-life: rapidly degraded peripherally; central CSF half-life estimated 10-30 minutes. Cycle: single dose protocols; no established multi-week cycles.

Use our peptide calculator for reconstitution math for either compound.

How Do the Benefits Compare?

DSIP benefits: improved sleep quality, increased slow-wave sleep, reduced sleep latency, stress reduction, improved sleep efficiency.

Orexin-A benefits: increased wakefulness and arousal, cognitive function in narcolepsy, pain modulation.

The overlap in benefits determines whether these peptides compete for the same use case or complement each other in a stack.

How Do the Side Effects Compare?

DSIP: Minimal adverse effects in human studies. Rare mild headache or dizziness. Long-term safety profile not established.

Orexin-A: Limited human safety data. Potential increased heart rate and blood pressure. Poor blood-brain-barrier penetration limits peripheral dosing.

Can You Stack DSIP and Orexin-A Together?

Many researchers combine DSIP and Orexin-A in stacking protocols. The different mechanisms mean they can potentially provide complementary effects without competing for the same receptors.

Complements CJC-1295/Ipamorelin bedtime dosing for synergistic sleep improvement and GH release during deep sleep phases. See our stacking guide for general principles.

Which Is Better: DSIP or Orexin-A?

There is no universal answer. DSIP may be preferable for researchers focused on improved sleep quality, while Orexin-A is stronger for increased wakefulness and arousal.

For the most comprehensive results, many researchers combine both. Review each compound's individual guide for detailed protocols: DSIP | Orexin-A.

Frequently Asked Questions